Nanosonics (NAN) AGM 2025 summary

Opening remarks and agenda

• Meeting opened with acknowledgment of traditional landowners, introduction of the Board, Company Secretary, and auditors, and a focus on infection prevention and the company's mission to improve safety through innovative technologies.

• Quorum confirmed with 330 proxies representing 72.79% of shares.

• Housekeeping instructions provided for both in-person and online attendees regarding questions and voting.

• Agenda included Chairman's address, CEO's address, formal business, and Q&A.

Financial performance review

• FY2025 revenue reached AUD 198.6 million, up 17% year-on-year (14% in constant currency).

• Capital revenue grew 9% to AUD 52.5 million; recurring revenue rose 20% to AUD 146.1 million.

• Profit before tax increased 72% to AUD 22.3 million (49% in constant currency).

• Cash flow strong at AUD 32 million; cash reserves at AUD 161.6 million with no debt.

Board and executive committee updates

• Gerard Dalbosco joined as Non-Executive Director and Chair of Audit and Risk Committee; Steven Sargent re-elected as Chairman.

• Lisa McIntyre stepped down after nearly six years of service.

• Board composition highlighted as diverse, independent, and with a mix of business, scientific, and medical expertise.